Microbix Biosystems Inc. (TSE:MBX – Get Rating) – Equities research analysts at Bloom Burton dropped their FY2023 earnings per share (EPS) estimates for shares of Microbix Biosystems in a research report issued on Monday, May 15th. Bloom Burton analyst A. Borovina now forecasts that the company will post earnings per share of $0.00 for the year, down from their prior estimate of $0.01. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.01 per share.
Microbix Biosystems Stock Down 1.2 %
Shares of Microbix Biosystems stock opened at C$0.42 on Wednesday. The business’s 50 day simple moving average is C$0.38 and its 200 day simple moving average is C$0.40. Microbix Biosystems has a 52-week low of C$0.30 and a 52-week high of C$0.57. The firm has a market cap of C$57.46 million, a PE ratio of 34.00 and a beta of 0.14. The company has a debt-to-equity ratio of 25.43, a quick ratio of 5.57 and a current ratio of 6.32.
Microbix Biosystems Company Profile
Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably test ingredients for immunoassays and quality assessment and proficiency testing controls (QAPs) that support sample collection devices.
Read More
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The MarketÂ
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
